Product
Ovarian function suppression
2 clinical trials
3 indications
Indication
Breast CancerIndication
HR+/HER2- Advanced Breast CancerIndication
Targeted TherapyClinical trial
Neoadjuvant Tucidinostat and Exemestane in Estrogen Receptor-Positive Early Breast Cancer （NeoTEE）Status: Completed, Estimated PCD: 2023-10-01
Clinical trial
A Prospective Cohort, Open, Phase II Clinical Study of Chidamide/Everolimus Combined With Endocrine Therapy for PIK3CA Wild-type/Mutant Hormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast CancerStatus: Recruiting, Estimated PCD: 2026-07-15